DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific synthetic expertise and methodologies from the Wright Group at Dartmouth College to investigators at Promiliad Biopharma in an effort to reduce Promiliad's REBACS strategy to the level of… More

DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific biophysical and synthetic expertise from the Anderson and Wright Groups at the University of Connecticut to investigators at Promiliad Biopharma in a joint effort to develop best-in- class… More

DESCRIPTION (provided by applicant): Antibiotic resistance among common pathogens is a serious public health problem because it compromises our ability to treat many infectious diseases. The problem has been compounded by the lack of discovery of new antib iotics that act in novel ways. Such… More

DESCRIPTION (provided by applicant): Antibiotic resistant pathogens, such as methicillin-resistant Staphylococcus aureus, are a significant public health problem which is compounded by the slow rate of development of new antibiotics. Investigators at Merck Research Laboratories recently reported on… More

DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner the drug discovery technology of the Promiliad Biopharma w ith the expertise of Professor Dennis McKay… More

DESCRIPTION (provided by applicant): This Phase II STTR proposal describes a collaborative effort between researchers in the Department of Pharmaceutical Sciences at the University of Connecticut and Promiliad Biopharma to develop efficacious antibiotics targeting both methicillin-resistant strains… More